<div id="readability-page-1"><p>Bayesian Capital Management LP acquired a new position in  Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The fund acquired 26,602 shares of the medical research company's stock, valued at approximately $4,036,000. Bayesian Capital Management LP owned 0.05% of Charles River Laboratories International at the end of the most recent reporting period.</p><ul><li>The 2 Worst Performing S&amp;P 500 Stocks YTD: Buy, Sell, or Avoid?</li></ul><p>A number of other hedge funds also recently bought and sold shares of CRL. Invesco Ltd. lifted its stake in shares of  Charles River Laboratories International by 11.6% in the 2nd quarter. Invesco Ltd. now owns 1,237,143 shares of the medical research company's stock worth $187,712,000 after purchasing an additional 128,785 shares during the period.  Russell Investments Group Ltd. increased its holdings in  Charles River Laboratories International by 59.8% during the second quarter. Russell Investments Group Ltd. now owns 31,175 shares of the medical research company's stock valued at $4,730,000 after buying an additional 11,667 shares during the last quarter.  Bank of Nova Scotia increased its holdings in  Charles River Laboratories International by 10,860.5% during the second quarter. Bank of Nova Scotia now owns 203,318 shares of the medical research company's stock valued at $30,849,000 after buying an additional 201,463 shares during the last quarter.  Balefire LLC raised its position in  Charles River Laboratories International by 39.4% in the second quarter. Balefire LLC now owns 13,494 shares of the medical research company's stock worth $2,047,000 after acquiring an additional 3,815 shares during the period.  Finally, Fifth Third Bancorp boosted its stake in shares of  Charles River Laboratories International by 47.1% during the 2nd quarter. Fifth Third Bancorp now owns 12,871 shares of the medical research company's stock worth $1,953,000 after acquiring an additional 4,124 shares during the last quarter. Hedge funds and other institutional investors own  98.91% of the company's stock. </p><h2>Charles River Laboratories International Stock Performance</h2><p>Shares of CRL stock opened at $194.34 on Friday. The firm has a market cap of $9.57 billion, a price-to-earnings ratio of -124.58, a PEG ratio of 6.88 and a beta of 1.63. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $199.66. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64. The company's 50 day moving average is $177.09 and its 200 day moving average is $162.91. </p><p>Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.32 by $0.11. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.The business's revenue was down .5% compared to the same quarter last year. During the same period last year, the business posted $2.59 EPS.  On average, sell-side analysts anticipate that  Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year. </p><h2>Analyst Ratings Changes</h2><p>CRL has been the subject of several recent research reports. Wall Street Zen lowered Charles River Laboratories International from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 8th. TD Cowen reduced their price target on shares of Charles River Laboratories International from $205.00 to $197.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, November 10th. Argus  set a $200.00 price objective on Charles River Laboratories International in a research note on Monday, November 17th. Robert W. Baird raised shares of Charles River Laboratories International from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and increased their price target for the company from $178.00 to $199.00 in a report on Thursday, November 6th. Finally, Mizuho raised their price target on Charles River Laboratories International from $155.00 to $174.00 and gave the stock a &#34;neutral&#34; rating in a research report on Friday, October 17th. One analyst  has rated the stock with a Strong Buy rating, ten have issued  a Buy rating, six have assigned  a Hold rating and one  has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $190.86.</p><p><b>Check Out Our Latest Stock Report on Charles River Laboratories International</b></p><h2>Charles River Laboratories International Profile</h2> (Free Report)<p>Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Charles River Laboratories International</li><li>How to Use the MarketBeat Dividend Calculator</li><li>3 Recently Downgraded Stocks to Avoid in 2026</li><li>Industrial Products Stocks Investing </li><li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li><li>Differences Between Momentum Investing and Long Term Investing </li><li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNSTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNSTA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Charles River Laboratories International Right Now?</h2><p>Before you consider Charles River Laboratories International, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.</p><p>While Charles River Laboratories International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Bayesian Capital Management LP acquired 26,602 shares of Charles River Laboratories International, valued at $4,036,000, in Q2. Other hedge funds also increased their holdings. CRL's stock opened at $194.34 with a market cap of $9.57 billion. Analysts have a consensus rating of 'Moderate Buy' with a price target of $190.86.</p>

Bayesian Capital Management LP Takes Position in Charles River Laboratories International, Inc. $CRL